1.Dosage form specifications
Chemical structural formula: C26H35F3O6
Dosage form specifications:
Eye drops: 0.004% (2.5ml: 0.1mg);
Compound eye drops of timolol maleate: 2.5ml: travoprost 0.1mg and timolol maleate 12.5mg (calculated as timolol)

2.Applicability
Reduce the elevated pressure limit in patients with open angle glaucoma or high intraocular pressure

3.Usage and dosage
Recommended dosage: once per night, 1 drop per time, drop into the affected eye.

4.Product advantages
Travoprost is a prostaglandin analogue developed by Alcon in the United States. It was launched in the United States in 2001 and has been sold in dozens of countries worldwide. It is currently one of the first-line drugs for treating glaucoma. Prostaglandin analogues can increase the excretion of aqueous humor, thereby reducing intraocular pressure.
Clinical trials have shown that travoprost significantly improves vision, astigmatism, and intraocular pressure at different times after treatment compared to timolol maleate; The incidence of adverse reactions is significantly lower than that of timolol maleate.
Glaucoma is a common chronic ophthalmic disease and the second leading cause of blindness worldwide. Its main characteristics include elevated intraocular pressure, damage to the optic nerve, and in severe cases, even loss of vision. This treatment market has great potential for development.
Travoprost eye drops are included in the reference catalog for the 22nd and 27th batches, and our company can provide A-state general agent foreign raw materials at a competitive price.